Nomon Bio Limited - Period Ending 2021-12-31

Nomon Bio Limited - Period Ending 2021-12-31


Nomon Bio Limited 11746176 false 2021-01-01 2021-12-31 2021-12-31 The principal activity of the company is providing consultancy services. Digita Accounts Production Advanced 6.30.9574.0 true 11746176 2021-01-01 2021-12-31 11746176 2021-12-31 11746176 core:CurrentFinancialInstruments 2021-12-31 11746176 core:CurrentFinancialInstruments core:WithinOneYear 2021-12-31 11746176 bus:SmallEntities 2021-01-01 2021-12-31 11746176 bus:AuditExemptWithAccountantsReport 2021-01-01 2021-12-31 11746176 bus:FullAccounts 2021-01-01 2021-12-31 11746176 bus:SmallCompaniesRegimeForAccounts 2021-01-01 2021-12-31 11746176 bus:RegisteredOffice 2021-01-01 2021-12-31 11746176 bus:Director1 2021-01-01 2021-12-31 11746176 bus:PrivateLimitedCompanyLtd 2021-01-01 2021-12-31 11746176 countries:EnglandWales 2021-01-01 2021-12-31 11746176 2020-01-01 2020-12-31 11746176 2020-12-31 11746176 core:CurrentFinancialInstruments 2020-12-31 11746176 core:CurrentFinancialInstruments core:WithinOneYear 2020-12-31 iso4217:GBP xbrli:pure

Registration number: 11746176

Nomon Bio Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2021

 

Nomon Bio Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 5

 

Nomon Bio Limited

Company Information

Director

Dr Michael O'Neill

Registered office

171 Windmill Rd
Ealing
London
Middlesex
W5 4DH

Accountants

Sterling Grove Accountants Limited
Certified Chartered
Fawley House
2 Regatta Place
Marlow Road
Bourne End
Buckinghamshire
SL8 5TD

 

Nomon Bio Limited

(Registration number: 11746176)
Balance Sheet as at 31 December 2021

Note

2021
£

2020
£

Current assets

 

Debtors

4

7,285

7,220

Cash at bank and in hand

 

19,060

27,721

 

26,345

34,941

Creditors: Amounts falling due within one year

5

(17,729)

(14,787)

Net assets

 

8,616

20,154

Capital and reserves

 

Called up share capital

1

1

Retained earnings

8,615

20,153

Shareholders' funds

 

8,616

20,154

For the financial year ending 31 December 2021 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 8 July 2022
 

.........................................
Dr Michael O'Neill
Director

 

Nomon Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2021

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
171 Windmill Rd
Ealing
London
Middlesex
W5 4DH
United Kingdom

These financial statements were authorised for issue by the director on 8 July 2022.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:The amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities.

Government grants

Government grants are recognised under the accrual model of grant recognition. This model requires the grant to be classified as either a revenue-based grant or a capital-based grant.

Government grants are recognised in profit or loss on a systematic basis over the periods in which the entity recognises expenses for the related costs for which the grants are intended to compensate.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset.

 

Nomon Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2021

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Nomon Bio Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2021

3

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2020 - 1).

4

Debtors

Current

2021
£

2020
£

Trade debtors

7,285

7,220

5

Creditors

Creditors: amounts falling due within one year

Note

2021
£

2020
£

Due within one year

 

Amounts owed to related parties

12,451

3,287

Accruals and deferred income

 

1,000

800

Corporation tax

 

4,278

10,700

 

17,729

14,787